Synopsis: Samir Ounzain is the CEO and Co-Founder of HAYA Therapeutics, a precision medicines company developing RNA-guided programmable therapeutics targeting the regulatory genome for serious health conditions including fibrosis. Samir discusses the current landscape as it relates to precision medicine and genomic medicine and what his team is hoping to achieve over the next year. He also talks about the evolution of his approach to fundraising and shares his thoughts on applying machine learning and AI at the intersection of biology. Finally, with a distributed team in both the US and Switzerland, he discusses the challenges that come with that, and how he approaches team building. Biography: Samir Ounzain is a molecular biologist with over 15 years of experience exploring the dark matter of the genome and its roles in development and disease. Prior to founding HAYA Therapeutics, Samir was a Project Leader and Research Fellow at the Lausanne University Hospital (CHUV), where his research efforts directly led to the discovery of hundreds of novel heart-enriched lncRNAs, most notably the lncRNAs CARMEN, Meteor and Wisper.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related